January 22, 2016 8:30am EST
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE:OPK) announced today that Marc D. Grodman, MD,
Chief Executive Officer of its BioReference/GeneDx subsidiaries, will
speak at this year’s Personalized
Medicine World Conference, Silicon Valley . Dr. Grodman’s
Presentation, titled “New Model of Clinical Genomics Collaboration”,
will highlight a unique partnership between GeneDx and health systems to
provide a complete genomic solution that facilitates improved patient
care, education, research opportunities and commercial R&D
collaborations.
As part of the “New Approaches in Cancer Dx” track, Dr. Grodman is
scheduled to present on January 26 th at 1:00 p.m. Pacific
Time in Track 3 of the conference. Details on his talk can be found at http://2016sv.pmwcintl.com/bio-marc-grodman .
The Personalized Medicine World Conference is an independent conference,
co-hosted with Stanford Health Care and UCSF, that brings together
experts across healthcare and biotechnology sectors to help further the
adoption of personalized medicine in the clinic. This year’s Silicon
Valley conference will be held on January 26 th through the 27 th
at the Computer History Museum in Mountain View, California.
About OPKO Health, Inc.
OPKO Health, Inc. is a diversified healthcare company that seeks to
establish industry-leading positions in large, rapidly growing markets.
Our diagnostics business includes Bio-Reference Laboratories, the
nation's third-largest clinical laboratory with a core genetic testing
business and a 420-person sales force to drive growth and leverage new
products, including the 4Kscore® prostate cancer test and the Claros®1
in-office immunoassay platform. Our pharmaceutical business features
Rayaldee™, a treatment for SHPT in stage 3-4 CKD patients with vitamin D
insufficiency (March 29, 2016 PDUFA date) and VARUBI™ for
chemotherapy-induced nausea and vomiting (oral formulation launched by
partner Tesaro, IV formulation in Phase 3). Our biologics business
includes hGH-CTP, a once-weekly human growth hormone injection (in Phase
3 and partnered with Pfizer), and a long-acting Factor VIIa drug for
hemophilia (entering Phase 2a). We also have production and distribution
assets worldwide, multiple strategic investments and an active business
development strategy. More information is available at www.opko.com .
About BioReference and GeneDx
GeneDx and its parent company BioReference Laboratories Inc. are members
of the OPKO Health, Inc. (NYSE: OPK) group of companies. BioReference is
the third largest clinical laboratory in the US and is a leader in
technological innovation in the industry. GeneDx is a world leader in
Genomics with an acknowledged expertise in rare and ultra rare genetic
disorders, as well as one of the broadest menus of sequencing services
available among commercial laboratories. GeneDx performs more clinical
Whole Exome Sequencing tests than any other diagnostic lab in the world.
The GeneDx mission is to make clinical testing affordable and available
to people with rare genetic conditions and their families. GeneDx
provides testing to patients and their families in more than 55
countries. To learn more, please visit www.bioreference.com
and www.genedx.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160122005245/en/
OPKO Health, Inc.
Carly Erickson, 202-600-4558
or
Tara
Mackay, 305-575-4100
Investor Relations
or
Media
Rooney
& Associates
Terry Rooney, 212-223-0689
or
Marion
Janic, 212-223-4017
or
Investors
LHA
Anne
Marie Fields, 212-838-3777
or
Bruce
Voss, 310-691-7100
Source: OPKO Health, Inc.
Released January 22, 2016
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page